{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:13:42Z","timestamp":1764000822016,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan","award":["ONC-GBM-001"],"award-info":[{"award-number":["ONC-GBM-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09363-2","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T10:01:47Z","timestamp":1711188107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predominance of MGMT promoter methylation among Pakistani glioblastoma patients"],"prefix":"10.1007","volume":"51","author":[{"given":"Noor","family":"Muhammad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Fasih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Loya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-3122","authenticated-orcid":false,"given":"Muhammad Usman","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"key":"9363_CR1","unstructured":"Global Cancer Statistics (2020) : https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/586-pakistan-fact-sheets.pdf. Date accessed: September 10, 2023"},{"key":"9363_CR2","doi-asserted-by":"publisher","first-page":"e011828","DOI":"10.1136\/bmjopen-2016-011828","volume":"6","author":"F Badar","year":"2016","unstructured":"Badar F, Mahmood S, Yusuf MA, Sultan F (2016) Epidemiology of cancers in Lahore, Pakistan, 2010\u20132012: a cross-sectional study. BMJ Open 6:e011828. https:\/\/doi.org\/10.1136\/bmjopen-2016-011828","journal-title":"BMJ Open"},{"key":"9363_CR3","doi-asserted-by":"publisher","first-page":"e0154347","DOI":"10.1371\/journal.pone.0154347","volume":"11","author":"EJ Maile","year":"2016","unstructured":"Maile EJ, Barnes I, Finlayson AE, Sayeed S, Ali R (2016) Nervous system and intracranial tumour incidence by ethnicity in England, 2001\u20132007: a descriptive epidemiological study. PLoS ONE 11:e0154347. https:\/\/doi.org\/10.1371\/journal.pone.0154347","journal-title":"PLoS ONE"},{"key":"9363_CR4","first-page":"81","volume":"27","author":"J Ahsan","year":"2015","unstructured":"Ahsan J, Hashmi SN, Muhammad I, Din HU, Butt AM, Nazir S, Azhar M (2015) Spectrum of central nervous system tumours\u2013a single center histopathological review of 761 cases over 5 years. J Ayub Med Coll Abbottabad 27:81\u201384","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"9363_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-006-9320-0","volume":"83","author":"E Crini\u00e8re","year":"2007","unstructured":"Crini\u00e8re E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre J-Y (2007) MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83:173\u2013179. https:\/\/doi.org\/10.1007\/s11060-006-9320-0","journal-title":"J Neurooncol"},{"key":"9363_CR6","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Simi\u0144ska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I (2022) Epidemiology of glioblastoma multiforme\u2013literature review. Cancers 14:2412. https:\/\/doi.org\/10.3390\/cancers14102412","journal-title":"Cancers"},{"key":"9363_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"9363_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"M Esteller","year":"2000","unstructured":"Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350\u20131354. https:\/\/doi.org\/10.1056\/NEJM200011093431901","journal-title":"N Engl J Med"},{"key":"9363_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"9363_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","volume":"9","author":"T Gorlia","year":"2008","unstructured":"Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981\u2009\u2013\u200922981\/CE. 3. Lancet Oncol 9:29\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(07)70384-4","journal-title":"Lancet Oncol"},{"key":"9363_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"9363_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jcp.25896","volume":"233","author":"MM Binabaj","year":"2018","unstructured":"Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Joudi Mashhad M, Hassanian SM, Anvari K, Avan A (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233:378\u2013386. https:\/\/doi.org\/10.1002\/jcp.25896","journal-title":"J Cell Physiol"},{"key":"9363_CR13","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s11064-014-1435-7","volume":"39","author":"H Yang","year":"2014","unstructured":"Yang H, Wei D, Yang K, Tang W, Luo Y, Zhang J (2014) The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis. Neurochem Res 39:2277\u20132287. https:\/\/doi.org\/10.1007\/s11064-014-1435-7","journal-title":"Neurochem Res"},{"key":"9363_CR14","doi-asserted-by":"publisher","unstructured":"Meng W, Jiang Y, Ma J (2017) Is the prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis. Cancer Manage Res 411\u2013425. https:\/\/doi.org\/10.2147\/CMAR.S140447","DOI":"10.2147\/CMAR.S140447"},{"key":"9363_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nop020","volume":"12","author":"AL Rivera","year":"2010","unstructured":"Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neurooncology 12:116\u2013121. https:\/\/doi.org\/10.1093\/neuonc\/nop020","journal-title":"Neurooncology"},{"key":"9363_CR16","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1078-0432.ccr-03-0384","volume":"10","author":"ME Hegi","year":"2004","unstructured":"Hegi ME, Diserens A-C, Godard S, Dietrich P-Y, Regli L, Ostermann S, Otten P, Van Melle G, De Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871\u20131874. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0384","journal-title":"Clin Cancer Res"},{"key":"9363_CR17","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s12032-011-9901-4","volume":"29","author":"K Tang","year":"2012","unstructured":"Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T (2012) Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol 29:1292\u20131296. https:\/\/doi.org\/10.1007\/s12032-011-9901-4","journal-title":"Med Oncol"},{"key":"9363_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11060-013-1102-x","volume":"113","author":"G-B Zhang","year":"2013","unstructured":"Zhang G-B, Cui X-L, Sui D-L, Ren X-H, Zhang Z, Wang Z-C, Lin S (2013) Differential molecular genetic analysis in glioblastoma multiforme of long-and short-term survivors: a clinical study in Chinese patients. J Neurooncol 113:251\u2013258. https:\/\/doi.org\/10.1007\/s11060-013-1102-x","journal-title":"J Neurooncol"},{"key":"9363_CR19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00701-009-0387-1","volume":"151","author":"Y Sonoda","year":"2009","unstructured":"Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, Tominaga T (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir 151:1349\u20131358. https:\/\/doi.org\/10.1007\/s00701-009-0387-1","journal-title":"Acta Neurochir"},{"key":"9363_CR20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s10147-010-0065-6","volume":"15","author":"Y Sonoda","year":"2010","unstructured":"Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T (2010) O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352\u2013358. https:\/\/doi.org\/10.1007\/s10147-010-0065-6","journal-title":"Int J Clin Oncol"},{"key":"9363_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-641","volume":"14","author":"M Kanemoto","year":"2014","unstructured":"Kanemoto M, Shirahata M, Nakauma A, Nakanishi K, Taniguchi K, Kukita Y, Arakawa Y, Miyamoto S, Kato K (2014) Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region. BMC Cancer 14:1\u201311. https:\/\/doi.org\/10.1186\/1471-2407-14-641","journal-title":"BMC Cancer"},{"key":"9363_CR22","doi-asserted-by":"publisher","first-page":"e23332","DOI":"10.1371\/journal.pone.0023332","volume":"6","author":"F Ohka","year":"2011","unstructured":"Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T (2011) The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS ONE 6:e23332. https:\/\/doi.org\/10.1371\/journal.pone.0023332","journal-title":"PLoS ONE"},{"key":"9363_CR23","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1227\/01.NEU.0000357325.90347.A1","volume":"65","author":"VT Cao","year":"2009","unstructured":"Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866\u2013875 discussion 875. https:\/\/doi.org\/10.1227\/01.NEU.0000357325.90347.A1","journal-title":"Neurosurgery"},{"key":"9363_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1440-1789.2008.00998.x","volume":"29","author":"CK Park","year":"2009","unstructured":"Park CK, Park SH, Lee SH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW (2009) Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology 29:443\u2013449. https:\/\/doi.org\/10.1111\/j.1440-1789.2008.00998.x","journal-title":"Neuropathology"},{"key":"9363_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4103\/0028-3886.103190","volume":"60","author":"GA Nehru","year":"2012","unstructured":"Nehru GA, Pai R, Samuel P, Chacko AG, Chacko G (2012) Status of O 6-methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India. Neurol India 60:481\u2013486. https:\/\/doi.org\/10.4103\/0028-3886.103190","journal-title":"Neurol India"},{"key":"9363_CR26","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.4103\/0028-3886.236974","volume":"66","author":"I Arora","year":"2018","unstructured":"Arora I, Gurav M, Rumde R, Dhanavade S, Kadam V, Kurani H, Shetty O, Goda JS, Shetty P, Moiyadi A (2018) MGMT gene promoter methylation and its correlation with clinicopathological parameters in glioblastomas. Neurol India 66:1106\u20131114. https:\/\/doi.org\/10.4103\/0028-3886.236974","journal-title":"Neurol India"},{"key":"9363_CR27","first-page":"5954","volume":"60","author":"WA Palmisano","year":"2000","unstructured":"Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA (2000) Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60:5954\u20135958","journal-title":"Cancer Res"},{"key":"9363_CR28","first-page":"793","volume":"59","author":"M Esteller","year":"1999","unstructured":"Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793\u2013797","journal-title":"Cancer Res"},{"key":"9363_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/noq162","volume":"13","author":"C-K Park","year":"2011","unstructured":"Park C-K, Kim J, Yim SY, Lee AR, Han JH, Kim C-Y, Park S-H, Kim TM, Lee S-H, Choi SH (2011) Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neurooncology 13:195\u2013202. https:\/\/doi.org\/10.1093\/neuonc\/noq162","journal-title":"Neurooncology"},{"key":"9363_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-6-115","volume":"6","author":"SE Combs","year":"2011","unstructured":"Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C (2011) Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 6:1\u20135. https:\/\/doi.org\/10.1186\/1748-717X-6-115","journal-title":"Radiat Oncol"},{"key":"9363_CR31","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3892\/ijo_00000305","volume":"34","author":"S Wemmert","year":"2009","unstructured":"Wemmert S, Bettscheider M, Alt S, Ketter R, Kammers K, Feiden W, Steudel W-I, Rahnenf\u00fchrer J, Urbschat S (2009) p15 promoter methylation-a novel prognostic marker in glioblastoma patients. Int J Oncol 34:1743\u20131748. https:\/\/doi.org\/10.3892\/ijo_00000305","journal-title":"Int J Oncol"},{"key":"9363_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000170088","volume":"32","author":"I Zawlik","year":"2008","unstructured":"Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H (2008) Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 32:21\u201329. https:\/\/doi.org\/10.1159\/000170088","journal-title":"Neuroepidemiology"},{"key":"9363_CR33","doi-asserted-by":"publisher","first-page":"18445","DOI":"10.1038\/s41598-020-75477-9","volume":"10","author":"L Ega\u00f1a","year":"2020","unstructured":"Ega\u00f1a L, Auzmendi-Iriarte J, Andermatten J, Villanua J, Ruiz I, Elua-Pinin A, Aldaz P, Querejeta A, Sarasqueta C, Zubia F (2020) Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital. Sci Rep 10:18445. https:\/\/doi.org\/10.1038\/s41598-020-75477-9","journal-title":"Sci Rep"},{"key":"9363_CR34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ijrobp.2011.12.086","volume":"84","author":"YS Kim","year":"2012","unstructured":"Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh C-O (2012) MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys 84:661\u2013667. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.086","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9363_CR35","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1200\/JCO.2009.23.0805","volume":"27","author":"M Weller","year":"2009","unstructured":"Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743\u20135750. https:\/\/doi.org\/10.1200\/JCO.2009.23.0805","journal-title":"J Clin Oncol"},{"key":"9363_CR36","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1002\/cncr.27441","volume":"118","author":"E Lechapt-Zalcman","year":"2012","unstructured":"Lechapt-Zalcman E, Levallet G, Dugue AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M (2012) O6\u2010methylguanine\u2010DNA methyltransferase (MGMT) promoter methylation and low MGMT\u2010encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 118:4545\u20134554. https:\/\/doi.org\/10.1002\/cncr.27441","journal-title":"Cancer"},{"key":"9363_CR37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/s-0042-1750779","volume":"17","author":"FA Mirza","year":"2022","unstructured":"Mirza FA, Baqai MWS, Hani U, Hulou M, Shamim MS, Enam SA, Pittman T (2022) Comparison of Glioblastoma Outcomes in two geographically and ethnically distinct patient populations in Disparate Health Care systems. Asian J Neurosurg 17:178\u2013188. https:\/\/doi.org\/10.1055\/s-0042-1750779","journal-title":"Asian J Neurosurg"},{"key":"9363_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11060-011-0668-4","volume":"106","author":"S-H Yang","year":"2012","unstructured":"Yang S-H, Lee KS, Yang HJ, Jeon BH, Lee YS, Nam SW, Chung D-S, Lee SW, Hong Y-K (2012) O 6-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas. J Neurooncol 106:243\u2013250. https:\/\/doi.org\/10.1007\/s11060-011-0668-4","journal-title":"J Neurooncol"},{"key":"9363_CR39","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/neuonc\/nou005","volume":"16","author":"RJ Molenaar","year":"2014","unstructured":"Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D, van Tilborg AA (2014) The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neurooncology 16:1263\u20131273. https:\/\/doi.org\/10.1093\/neuonc\/nou005","journal-title":"Neurooncology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09363-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09363-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09363-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T20:20:26Z","timestamp":1738700426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09363-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9363"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09363-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2024,3,23]]},"assertion":[{"value":"15 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board (IRB) of Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) Lahore (Date: 19-07-2011\/No. ONC-GBM-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Owing to the retrospective study, the IRB granted the waiver of the written informed consent from the study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"433"}}